Celldex Therapeutics, Inc.
CLDX
$32.55
$0.551.72%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 866.00K | 1.55M | 2.60M | 5.79M | 7.56M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 866.00K | 1.55M | 2.60M | 5.79M | 7.56M |
| Cost of Revenue | 265.46M | 245.07M | 216.68M | 199.01M | 184.50M |
| Gross Profit | -264.60M | -243.53M | -214.08M | -193.22M | -176.94M |
| SG&A Expenses | 44.47M | 43.84M | 42.16M | 41.53M | 40.27M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 309.93M | 288.91M | 258.84M | 240.54M | 224.77M |
| Operating Income | -309.06M | -287.37M | -256.24M | -234.75M | -217.21M |
| Income Before Tax | -283.65M | -258.76M | -224.53M | -199.61M | -178.85M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -283.65 | -258.76 | -224.53 | -199.61 | -178.85 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -283.65M | -258.76M | -224.53M | -199.61M | -178.85M |
| EBIT | -309.06M | -287.37M | -256.24M | -234.75M | -217.21M |
| EBITDA | -305.70M | -283.99M | -252.86M | -231.40M | -213.94M |
| EPS Basic | -4.27 | -3.90 | -3.38 | -3.01 | -2.70 |
| Normalized Basic EPS | -2.67 | -2.43 | -2.11 | -1.88 | -1.69 |
| EPS Diluted | -4.27 | -3.90 | -3.38 | -3.01 | -2.70 |
| Normalized Diluted EPS | -2.67 | -2.43 | -2.11 | -1.88 | -1.69 |
| Average Basic Shares Outstanding | 265.87M | 265.68M | 265.55M | 265.42M | 265.05M |
| Average Diluted Shares Outstanding | 265.87M | 265.68M | 265.55M | 265.42M | 265.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |